QPPV.COM KNOWLEDGE ASSESSMENT

Cenobamate: Clinical Context, Liver-Injury Signal and Pharmacovigilance

Test your understanding of the concepts covered by Cenobamate (Ontozry/Xcopri): From Drug Discovery to Severe Liver Injury and Evolving Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 A patient with elevated liver enzymes also has fever, rash and eosinophilia. Which assessment is most appropriate?

Classify the case automatically as isolated drug-induced liver injury. Consider whether hepatic involvement is part of DRESS or another systemic hypersensitivity presentation. Exclude DRESS because liver abnormalities are not associated with systemic reactions. Assess only the liver tests because other symptoms are irrelevant to pharmacovigilance.

Question 2 of 10 Why should cenobamate case records capture the titration history rather than only the current maintenance dose?

The current dose has no clinical relevance once treatment begins. The exposure trajectory and timing of dose increases may help interpret the risk period and the event. Titration history is required only to determine the patient's seizure type. The maintenance dose always identifies the dose at which an event began.

Question 3 of 10 What does the article imply about the difference between pre-authorisation and post-authorisation safety evidence for cenobamate?

Clinical trials identified hepatic enzyme elevations, while later post-marketing evidence supported stronger recognition and controls for clinically significant liver injury. No hepatic findings existed before approval, so post-marketing reports introduced the first possible liver concern. Post-marketing reports are automatically more reliable than trial data and require no assessment. Pre-authorisation findings make subsequent safety evidence unnecessary.

Question 4 of 10 A patient with pre-existing hepatic impairment experiences a liver event while taking cenobamate. Which information is especially important to retain?

Only the patient's seizure frequency after the event. Baseline hepatic status and prescribed dose, because hepatic impairment affects exposure and dosing context. Only the date cenobamate received marketing authorisation. The baseline liver status should be omitted to avoid influencing causality assessment.

Question 5 of 10 Which laboratory pattern does the U.S. label identify as an important predictor of severe liver injury?

Transaminases greater than three times the reference range together with total bilirubin greater than two times the reference range. Any ALT result above the reference range, regardless of other findings. Low bilirubin with normal transaminases. An isolated change in alkaline phosphatase without clinical context.

Question 6 of 10 Why should a global organisation map local monitoring requirements instead of adopting one jurisdiction's wording as a universal instruction?

Because EU and U.S. requirements are related but not identical, and local product information governs the applicable implementation. Because liver monitoring is optional in every jurisdiction. Because local requirements apply only to clinical trials. Because a global instruction cannot contain any monitoring information.

Question 7 of 10 A serious suspected liver injury leads clinicians to consider stopping cenobamate. Which statement best captures the competing safety consideration described in the article?

Cenobamate must always be stopped abruptly, regardless of clinical circumstances. Withdrawal is generally gradual, but safety concerns may require abrupt withdrawal; seizure worsening after abrupt cessation is also relevant. Discontinuation has no potential consequences for seizure control. The medicine should be continued until causality is proven beyond doubt.

Question 8 of 10 Why is disproportionality analysis alone insufficient to determine whether cenobamate caused a liver-injury signal?

Statistical methods cannot detect any safety concerns. A statistical association can generate a hypothesis, but assessment also requires clinical review, case quality, alternative explanations and cumulative benefit-risk evaluation. Disproportionality analysis proves causality whenever a signal is detected. Only randomised trials can contribute to post-authorisation signal evaluation.

Question 9 of 10 Why is the full concomitant-medication history especially important when evaluating a serious hepatic event during cenobamate treatment?

Cenobamate is normally used without other antiseizure medicines. Polytherapy is common, other medicines may have hepatic liabilities, and cenobamate can affect exposure to some concomitant medicines. Concomitant medicines determine whether the patient has epilepsy. Recording other medicines is necessary only when the event is non-serious.

Question 10 of 10 Which statement best explains why most severe cases occurring during combination treatment do not, by themselves, identify the causal medicine?

Combination treatment makes causality assessment impossible. The observation highlights the importance of polytherapy but does not establish which medicine caused an individual case. The medicine used for the longest time must be causal. All medicines taken together should be assigned equal causality.

Cenobamate: Clinical Context, Liver-Injury Signal and Pharmacovigilance

Cookie Settings